SCHEMBL3629623

SCHEMBL3629623

O=C(Nc1scc(-c2ccc(F)cc2)c1C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.80

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.80
RAB9A P51151 2/20 0.80
KMT2A Q03164 2/20 0.80
NLRP3 Q96P20 1/20 0.80
NPC1 O15118 1/20 0.78
ANO1 Q5XXA6 17/20 0.74
ANO2 Q9NQ90 1/20 0.73
TP53 P04637 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3628382 1.00 MEN1 (0.80) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3631114 0.94 ANO1 (0.83) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3627477 0.89 MEN1 (1.00) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL12271278 0.89 ANO1 (0.80) MEN1RAB9AKMT2ANLRP3ANO1
SCHEMBL3630966 0.89 MEN1 (0.77) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3631123 0.88 ANO1 (0.75) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3626823 0.88 ANO1 (0.75) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3629758 0.88 MEN1 (0.80) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3629710 0.88 MEN1 (1.00) MEN1RAB9AKMT2ANLRP3NPC1
SCHEMBL3630211 0.88 MEN1 (0.78) MEN1RAB9AKMT2ANLRP3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263641-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2012-09-11 US claimed
CN-101854933-A Compounds that modulate intracellular calcium CALCIMEDICA INC 2010-10-06 CN claimed
EP-2200607-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2010-06-30 EP claimed
US-20090137659-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2009-05-28 US claimed
WO-2009035818-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2009-03-19 WO claimed
US-8524765-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-09-03 US disclosed
US-20120289587-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-11-15 US disclosed
US-8263641-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2012-09-11 US disclosed
CN-101854933-A Compounds that modulate intracellular calcium CALCIMEDICA INC 2010-10-06 CN disclosed
EP-2200607-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2010-06-30 EP disclosed
US-20090137659-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2009-05-28 US disclosed
WO-2009035818-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289587-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MEN1 2958/4885RAB9A 1174/4885KMT2A 4706/4885
US-20090137659-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MEN1 2958/4885RAB9A 1174/4885KMT2A 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.